Citation: pineda am et al.Transcatheter aortic valve replacement for patients with severe bicuspid aortic stenosis.Am heart j.2020 jun;224:105-112.Doi: 10.1016/j.Ahj.2020.02.003.Epub 2020 feb 8.Earliest date of publish used for date of event.Medtronic products referenced: corevalve (pma# p130021, pro code npt), evolut r (pma# p130021, pro code npt).Earliest approved product used for product code and pma#.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.If information is provided in the future, a supplemental report will be issued.
|
Medtronic received information from a literature article regarding an evaluation of the outcomes following transcatheter aortic valve replacement (tavr) in patients with bicuspid aortic valve stenosis compared to patients with trileaflet aortic valve stenosis.All data were retrospectively collected from a single center between april 2011 and november 2016.The study population included 567 patients (50 with bicuspid aortic valve stenosis, 517 with trileaflet aortic valve stenosis) and was predominantly male with a median age of 81 years and 88.4% were white.Of those, 333 patients were implanted with medtronic corevalve or evolut r self-expanding transcatheter valves.No serial numbers were provided.Among all patients treated with self-expanding transcatheter valves (corevalve or evolut r), 71 all-cause deaths occurred within two years after tavr.No further details were provided about the deaths.Based on the available information, medtronic product was not directly associated with the deaths.Among all patients in the study population, intra-operative adverse events included: valve malposition requiring intervention, ventricular perforation or tamponade, annular rupture, conversion to open-heart surgery, and aortic dissection.Based on the available information, medtronic product may have been associated with these adverse events.Among all patients treated with self-expanding transcatheter valves (corevalve or evolut r), post-operative in-hospital adverse events included: new permanent pacemaker implantation, ischemic stroke, unplanned cardiac or vascular surgery, new onset atrial fibrillation, mild to severe paravalvular regurgitation/leak, major vascular complications, and life-threatening or disabling bleeding.Based on the available information, medtronic product was associated with these adverse events.No additional adverse patient effects or product performance issues were reported.
|